{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:10:06Z","timestamp":1790082606805,"version":"4.0.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Cost comparisons of psoriasis biologics rely on list prices, but confidential rebates can substantially alter real costs and are often hidden even from prescribers. Ireland\u2019s framework agreement mandates a transparent 37% price cut plus a 12.5% rebate once a biosimilar enters the market, but deeper discounts for best-value biologics stay confidential. European tendering data show actual discounts of 80\u201390% off list price, meaning cost-minimization analyses using list prices alone risk misleading clinicians. We propose an approach similar to that in Scotland or Denmark: sharing relative net-cost rankings with prescribers without disclosing confidential absolute prices.<\/jats:p>","DOI":"10.1093\/ced\/llag368","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:50:23Z","timestamp":1787226623000},"source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u2018Cost differences between psoriasis biologics: implications for the Irish High Tech Scheme\u2019"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5104-5776","authenticated-orcid":false,"given":"Sophie","family":"Diong","sequence":"first","affiliation":[{"name":"Dermatology Department, Our Lady of Lourdes Hospital , Drogheda, Co Louth ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-3462","authenticated-orcid":false,"given":"Niamh","family":"Kearney","sequence":"additional","affiliation":[{"name":"Dermatology Department, Our Lady of Lourdes Hospital , Drogheda, Co Louth ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026092208221956100_llag368-B1","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/ced\/llag145","article-title":"Cost differences between psoriasis biologics: implications for the Irish High Tech Scheme","volume":"51","author":"Conlon","year":"2026","journal-title":"Clin Exp Dermatol"},{"key":"2026092208221956100_llag368-B2","volume-title":"Best-Value Biological Medicines \u2013 Ustekinumab","author":"Barry","year":"2026"},{"key":"2026092208221956100_llag368-B3","volume-title":"The Framework Agreement on the Supply and Pricing of Medicines (FASPM) 2026\u20132029","author":"Department of Health","year":"2026"},{"key":"2026092208221956100_llag368-B4","volume-title":"Best-Value Medicines","author":"Health Service Executive","year":"2026"},{"key":"2026092208221956100_llag368-B5","doi-asserted-by":"crossref","first-page":"591134","DOI":"10.3389\/fphar.2020.591134","article-title":"The expiry of Humira\u00ae market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures","volume":"11","author":"Moorkens","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag368\/70749902\/llag368.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag368\/70749902\/llag368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:22:27Z","timestamp":1790079747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag368\/8767648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":5,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag368","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"llag368"}}